| Budget Amount *help |
¥100,490,000 (Direct Cost: ¥77,300,000、Indirect Cost: ¥23,190,000)
Fiscal Year 2011: ¥20,280,000 (Direct Cost: ¥15,600,000、Indirect Cost: ¥4,680,000)
Fiscal Year 2010: ¥20,280,000 (Direct Cost: ¥15,600,000、Indirect Cost: ¥4,680,000)
Fiscal Year 2009: ¥20,280,000 (Direct Cost: ¥15,600,000、Indirect Cost: ¥4,680,000)
Fiscal Year 2008: ¥19,630,000 (Direct Cost: ¥15,100,000、Indirect Cost: ¥4,530,000)
Fiscal Year 2007: ¥20,020,000 (Direct Cost: ¥15,400,000、Indirect Cost: ¥4,620,000)
|
|---|
| Research Abstract |
In this study, we demonstrated that the epigenetic regulation of transcription by Evi-1 is essential for its leukemogenic capacity. We also revealed the novel molecular mechanisms by which the loss-of-function of AML1 promotes leukemogenesis, using our Aml1 conditional knockout mice. Furthermore, using newly generated Evi-1 conditional knockout mice and Evi-1-ires-GFP knock-in mice, we demonstrated a distinctive relationship between Evi-1 and the phenotype of hematopoietic stem cells or leukemic stem cells. These results provide a foundation to develop novel molecular targeted therapies for refractory hematological malignancies.
|
